^
Association details:
| Biomarker: | MLL3 mutation + TMB-H |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
497P - Investigating the potential relationship between KMT2C/KMT2D mutations and immune checkpoint inhibitor (ICI) in colorectal cancer (CRC)
Published date:
09/14/2020
Excerpt:
...we found the median TMB score (69.08 vs.14.37) was significantly different between KMT2C/2D MT and WT group (R squared 0.5527, 95% CI -73.8 to -35.63, p<0.0001), and the median OS differed widely (34 vs. 13 months) in KMT2C/2D MT and WT group (HR 0.46, 95% CI 0.24 to 0.88, p<0.05) ; the results supported that mutations in KMT2C/2D was associated with higher TMB and OS with ICI treatment.
